investors@edesabiotech.com
Condensed Interim Consolidated Statements of Operations
(Unaudited)
Three Months Ended
---------------------------------------
December 31, 2024 December 31,2023
------------------- ------------------
Expenses:
Research and development 1,019,818 704,458
General and
administrative 878,871 1,152,971
-------------- -------------
Loss from operations (1,898,689) (1,857,429)
Other Income (Loss):
Reimbursement grant
income 301,195 120,834
Other income (loss) (19,759) 58,144
-------------- -------------
Net loss (1,617,253) (1,678,451)
Exchange differences on
translation 18,656 (572)
-------------- -------------
Net comprehensive loss $ (1,598,597) $ (1,679,023)
============== =============
Weighted average number of
common shares 3,345,135 3,128,024
Loss per common share -
basic and diluted $ (0.48) $ (0.54)
-------------- -------------
Condensed Interim Consolidated Balance Sheets
(Unaudited)
December 31, 2024 September 30, 2024
------------------- --------------------
Assets:
Cash and cash equivalents $ 1,563,502 $ 1,037,320
Other current assets 508,426 638,302
Non-current assets 2,092,253 2,138,360
--------------- ----------------
Total Assets $ 4,164,181 $ 3,813,982
=============== ================
Liabilities and shareholders'
equity:
Current liabilities $ 1,900,219 $ 1,832,827
Shareholders' equity 2,263,962 1,981,155
--------------- ----------------
Total liabilities and
shareholders' equity $ 4,164,181 $ 3,813,982
=============== ================
Condensed Interim Consolidated Statements of Cash
Flows
(Unaudited)
Three Months Ended
---------------------------------------
December 31, 2024 December 31,2023
------------------- ------------------
Cash flows from operating
activities:
Net loss $ (1,617,253) $ (1,678,451)
Adjustments for non-cash
items 124,292 229,388
Change in working capital
items (24,242) 42,535
-------------- -------------
Net cash used in operating
activities (1,517,203) (1,406,528)
Net cash provided by
financing activities 2,071,545 305,742
Effect of exchange rate
changes on cash and cash
equivalents (28,160) 7,176
-------------- -------------
Net change in cash and cash
equivalents 526,182 (1,093,610)
Cash and cash equivalents,
beginning of period 1,037,320 5,361,397
-------------- -------------
Cash and cash equivalents,
end of period $ 1,563,502 $ 4,267,787
============== =============
(END) Dow Jones Newswires
February 14, 2025 16:15 ET (21:15 GMT)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。